Puma Biotechnology Inc (NASDAQ: PBYI) has a price-to-earnings ratio of 6.44x that is above its average ratio. Additionally, the 36-month beta value for PBYI is 1.08. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PBYI is 34.85M and currently, short sellers hold a 8.56% ratio of that float. The average trading volume of PBYI on December 06, 2024 was 377.60K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PBYI) stock’s latest price update
The stock price of Puma Biotechnology Inc (NASDAQ: PBYI) has dropped by -0.33 compared to previous close of 3.07. Despite this, the company has seen a fall of -9.73% in its stock price over the last five trading days. businesswire.com reported 2024-12-04 that LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule 5635(c)(4).
PBYI’s Market Performance
PBYI’s stock has fallen by -9.73% in the past week, with a monthly drop of 0.00% and a quarterly rise of 31.90%. The volatility ratio for the week is 7.36% while the volatility levels for the last 30 days are 10.20% for Puma Biotechnology Inc The simple moving average for the past 20 days is 1.11% for PBYI’s stock, with a -18.12% simple moving average for the past 200 days.
Analysts’ Opinion of PBYI
Many brokerage firms have already submitted their reports for PBYI stocks, with Citigroup repeating the rating for PBYI by listing it as a “Buy.” The predicted price for PBYI in the upcoming period, according to Citigroup is $11 based on the research report published on September 28, 2021 of the previous year 2021.
BofA/Merrill, on the other hand, stated in their research note that they expect to see PBYI reach a price target of $9. The rating they have provided for PBYI stocks is “Underperform” according to the report published on June 25th, 2020.
Goldman gave a rating of “Sell” to PBYI, setting the target price at $8 in the report published on October 08th of the previous year.
PBYI Trading at 6.15% from the 50-Day Moving Average
After a stumble in the market that brought PBYI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.41% of loss for the given period.
Volatility was left at 10.20%, however, over the last 30 days, the volatility rate increased by 7.36%, as shares surge +1.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.92% upper at present.
During the last 5 trading sessions, PBYI fell by -9.44%, which changed the moving average for the period of 200-days by -48.05% in comparison to the 20-day moving average, which settled at $3.03. In addition, Puma Biotechnology Inc saw -29.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PBYI starting from MILLER MICHAEL PATRICK, who sale 23,358 shares at the price of $3.49 back on Aug 12 ’24. After this action, MILLER MICHAEL PATRICK now owns 47,000 shares of Puma Biotechnology Inc, valued at $81,466 using the latest closing price.
MILLER MICHAEL PATRICK, the Director of Puma Biotechnology Inc, proposed sale 23,358 shares at $3.76 during a trade that took place back on Aug 12 ’24, which means that MILLER MICHAEL PATRICK is holding shares at $87,826 based on the most recent closing price.
Stock Fundamentals for PBYI
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.69 for the gross margin
The net margin for Puma Biotechnology Inc stands at 0.1. The total capital return value is set at 0.29. Equity return is now at value 42.32, with 10.95 for asset returns.
Based on Puma Biotechnology Inc (PBYI), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at 0.43. The debt to equity ratio resting at 1.1. The interest coverage ratio of the stock is 2.46.
Currently, EBITDA for the company is 47.52 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 0.7. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 1.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.42.
Conclusion
In conclusion, Puma Biotechnology Inc (PBYI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
